XBI is trading 3.4% down at $163.72 as investors appear to take profits following Moderna’s dramatic cancer-vaccine-driven surge.
- Edesa Biotech’s $25 million stock offering added pressure to biotech sentiment.
- Treasury yields rebounded and major U.S. indexes traded lower, weakening risk appetite.
- XBI had risen 5.90% to $169.55 on August 19, before reversing part of that rally.